Laboratories that digitize their slides often stall at the next step: running AI on them. Each algorithm tends to arrive with its own viewer and license, so testing several tools means juggling separate systems.
Leica Biosystems has added two Paige applications from Tempus to its Aperio AI Store, a catalog of partner algorithms inside the Aperio HALO AP image management system. "Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience," said Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems.
One model, more than 40 cancer types
Paige PanCancer Detect flags tissue suspicious for cancer across more than 40 cancer types in whole slide images (WSIs). It runs on Virchow, a foundation model that learned from 1.5 million slides from roughly 100,000 patients. Rather than one model per organ, Virchow learns general tissue features that transfer to rare cancers with little labeled data. Tempus reports a specimen-level area under the curve (AUC) of 0.95 across nine common and seven rare cancers.
A prostate suite with a regulatory record
The Paige Prostate suite covers three steps of prostate biopsy review:
- Paige Prostate Detect: highlights foci suspicious for cancer
- Paige Prostate Grade & Quantify: assigns Gleason patterns and measures tumor burden
- Paige Perineural Invasion: flags cancer growing along nerves
In one study, the tools cut slide reading time by about 20 percent. Paige Prostate Detect was the first AI tool in pathology to receive FDA marketing authorization, and the suite later gained EU In Vitro Diagnostic Regulation (IVDR) certification. All four are research use only in the Aperio AI Store.
| Application | Tissue scope | Prior regulatory status |
|---|---|---|
| Paige PanCancer Detect | More than 40 cancer types | Research use only |
| Paige Prostate Detect | Prostate needle biopsies | FDA De Novo (2021); EU IVDR (2025) |
| Paige Prostate Grade & Quantify | Prostate needle biopsies | EU IVDR (2025) |
| Paige Perineural Invasion | Prostate needle biopsies | EU IVDR (2025) |
Testing the single-workspace model
The applications will be demonstrated at the Digital Pathology Association's Pathology Visions 2026, October 16–18 in San Diego. As foundation models in cancer research multiply, the test is whether one workspace helps laboratories run several of them at once.
This article is based on a press release issued by Leica Biosystems and was produced under The Scientist's Editorial Policies.
